Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT05909462 |
| Other study ID # |
2023-56 |
| Secondary ID |
Deniz IpekMehmet |
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
January 21, 2023 |
| Est. completion date |
May 24, 2023 |
Study information
| Verified date |
June 2023 |
| Source |
Hitit University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Objectives: In this study, we aimed to compare the efficacy of ultrasonography-guided
suprascapular nerve block and intra-articular shoulder injection treatment in terms of joint
range of motion, pain and functional status in patients with adhesive capsulitis (AC).
Patients and Methods: 60 patients AC were included in our study. The patients were randomized
into two groups according to the sealed envelope method. In the evaluation of the patients
before the injection, age, gender, body mass index (BMI), occupation, education, duration of
complaint, symptomatic side and dominant hand information were recorded. In the first group,
2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine injection were mixed with the
posterior approach method into the shoulder joint under the guidance of ultrasonography
(USG). The second group underwent suprascapular nerve block (SSNB) injection with 2 ml of 40
mg triamcinolone acetonide and 4 ml of 1% lidocaine under USG guidance. Shoulder range of
motion (ROM), visual analog scale (VAS) scores and Shoulder Pain and Disability Index (SPADI)
scores were compared before the injection, on the tenth day after the injection and at the
third month after the injection.
Conclusion: As a result of our study, although it was observed that both methods provided
improvement in the treatment process, the significant improvement in the SSNB group indicates
that it is a more reliable treatment method in AC treatment.
Description:
Sixty patients AC who applied to our Orthopedics-Traumatology and Physical
Medicine-Rehabilitation Outpatient Clinic were included in our study. The study was approved
by the Hitit University Clinical Research Ethics Committee (Decision number:2023-56). A
well-informed written consent was obtained from all participants according to the principles
of the Declaration of Helsinki. Patients with an age range of 18-65 years, adapting to the
treatment program to be applied, diagnosed with unilateral stage 2-3 AC, no shoulder trauma
in the last 3 months, no shoulder injections, no bleeding disorder, no history of malignancy,
inflammatory disease and stroke were included in the study. The patients were randomized into
two groups according to the sealed envelope method. In the evaluation of the patients before
the injection, age, gender, body mass index (BMI), occupation, education, duration of
complaint, symptomatic side and dominant hand information were recorded. Injections were made
to the patients by the physiatrist and anesthetist researcher under the guidance of Logiq V2
portable USG device. In the first group, 2 ml of 40 mg triamcinolone acetonide and 4 ml of 1%
lidocaine injection were mixed with the posterior approach method into the shoulder joint
under the guidance of USG. The second group underwent suprascapular nerve block injection
with 2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine under USG guidance. In
addition, pendulum and ladder-finger exercises were given to both groups as a home exercise
program. Shoulder range of motion (ROM), visual analog scale (VAS) scores and Shoulder Pain
and Disability Index (SPADI) scores were compared before the injection, on the tenth day
after the injection and at the third month after the injection.
